PURPOSE: Patients with mixed lineage leukemia (MLL)-rearranged B-lymphoblastic leukemias (B-ALL) have an unfavorable prognosis and require intensified treatment. Multiple MLL fusion partners have been identified, complicating the diagnostic evaluation of MLL rearrangements. We analyzed molecular markers of MLL rearrangement for use in rapid diagnostic assays and found the immunomodulatory protein, Galectin-1 (Gal-1), to be selectively expressed in MLL-rearranged B-ALL. EXPERIMENTAL DESIGN: Transcriptional profiling of ALL subtypes revealed selective overexpression of Gal-1 in MLL-rearranged ALLs. For this reason, we analyzed Gal-1 protein expression in MLL-germline and MLL-rearranged adult and infant pediatric B-ALLs and cell lines by immunoblotting, immunohistochemistry, and intracellular flow cytometry of viable tumor cell suspensions. Because deregulated gene expression in MLL-rearranged leukemias may be related to the altered histone methyltransferase activity of the MLL fusion protein complex, we also analyzed histone H3 lysine 79 (H3K79) dimethylation in the LGALS1 promoter region using chromatin immunoprecipitation. RESULTS: Gal-1 transcripts were significantly more abundant in MLL-rearranged B-ALLs. All 32 primary MLL-rearranged B-ALLs exhibited abundant Gal-1 immunostaining, regardless of the translocation partner, whereas only 2 of 81 germline-MLL B-ALLs expressed Gal-1. In addition, Gal-1 was selectively detected in newly diagnosed MLL-rearranged B-ALLs by intracellular flow cytometry. The LGALS1 promoter H3K79 was significantly hypermethylated in MLL-rearranged B-ALLs compared with MLL-germline B-ALLs and normal pre-B cells. CONCLUSION: In B-ALL, Gal-1 is a highly sensitive and specific biomarker of MLL rearrangement that is likely induced by a MLL-dependent epigenetic modification. Copyright 2010 AACR.
PURPOSE:Patients with mixed lineage leukemia (MLL)-rearranged B-lymphoblastic leukemias (B-ALL) have an unfavorable prognosis and require intensified treatment. Multiple MLL fusion partners have been identified, complicating the diagnostic evaluation of MLL rearrangements. We analyzed molecular markers of MLL rearrangement for use in rapid diagnostic assays and found the immunomodulatory protein, Galectin-1 (Gal-1), to be selectively expressed in MLL-rearranged B-ALL. EXPERIMENTAL DESIGN: Transcriptional profiling of ALL subtypes revealed selective overexpression of Gal-1 in MLL-rearranged ALLs. For this reason, we analyzed Gal-1 protein expression in MLL-germline and MLL-rearranged adult and infant pediatric B-ALLs and cell lines by immunoblotting, immunohistochemistry, and intracellular flow cytometry of viable tumor cell suspensions. Because deregulated gene expression in MLL-rearranged leukemias may be related to the altered histone methyltransferase activity of the MLL fusion protein complex, we also analyzed histone H3 lysine 79 (H3K79) dimethylation in the LGALS1 promoter region using chromatin immunoprecipitation. RESULTS:Gal-1 transcripts were significantly more abundant in MLL-rearranged B-ALLs. All 32 primary MLL-rearranged B-ALLs exhibited abundant Gal-1 immunostaining, regardless of the translocation partner, whereas only 2 of 81 germline-MLL B-ALLs expressed Gal-1. In addition, Gal-1 was selectively detected in newly diagnosed MLL-rearranged B-ALLs by intracellular flow cytometry. The LGALS1 promoter H3K79 was significantly hypermethylated in MLL-rearranged B-ALLs compared with MLL-germline B-ALLs and normal pre-B cells. CONCLUSION: In B-ALL, Gal-1 is a highly sensitive and specific biomarker of MLL rearrangement that is likely induced by a MLL-dependent epigenetic modification. Copyright 2010 AACR.
Authors: Marta A Toscano; Germán A Bianco; Juan M Ilarregui; Diego O Croci; Jorge Correale; Joseph D Hernandez; Norberto W Zwirner; Francoise Poirier; Eleanor M Riley; Linda G Baum; Gabriel A Rabinovich Journal: Nat Immunol Date: 2007-06-24 Impact factor: 25.606
Authors: Victor L J L Thijssen; Ruben Postel; Ricardo J M G E Brandwijk; Ruud P M Dings; Irina Nesmelova; Sietske Satijn; Nicole Verhofstad; Yusaku Nakabeppu; Linda G Baum; Jeroen Bakkers; Kevin H Mayo; Françoise Poirier; Arjan W Griffioen Journal: Proc Natl Acad Sci U S A Date: 2006-10-16 Impact factor: 11.205
Authors: Scott A Armstrong; Jane E Staunton; Lewis B Silverman; Rob Pieters; Monique L den Boer; Mark D Minden; Stephen E Sallan; Eric S Lander; Todd R Golub; Stanley J Korsmeyer Journal: Nat Genet Date: 2001-12-03 Impact factor: 38.330
Authors: Frédéric van den Brûle; Stéphane Califice; Frédérique Garnier; Pedro L Fernandez; Andrew Berchuck; Vincent Castronovo Journal: Lab Invest Date: 2003-03 Impact factor: 5.662
Authors: Natalia Rubinstein; Mariano Alvarez; Norberto W Zwirner; Marta A Toscano; Juan M Ilarregui; Alicia Bravo; José Mordoh; Leonardo Fainboim; Osvaldo L Podhajcer; Gabriel A Rabinovich Journal: Cancer Cell Date: 2004-03 Impact factor: 31.743
Authors: Marieke H van der Linden; Maria Grazia Valsecchi; Paola De Lorenzo; Anja Möricke; Gritta Janka; Thierry M Leblanc; Maria Felice; Andrea Biondi; Myriam Campbell; Ian Hann; Jeffrey E Rubnitz; Jan Stary; Tomasz Szczepanski; Ajay Vora; Alina Ferster; Liisa Hovi; Lewis B Silverman; Rob Pieters Journal: Blood Date: 2009-08-05 Impact factor: 22.113
Authors: Eng-Juh Yeoh; Mary E Ross; Sheila A Shurtleff; W Kent Williams; Divyen Patel; Rami Mahfouz; Fred G Behm; Susana C Raimondi; Mary V Relling; Anami Patel; Cheng Cheng; Dario Campana; Dawn Wilkins; Xiaodong Zhou; Jinyan Li; Huiqing Liu; Ching-Hon Pui; William E Evans; Clayton Naeve; Limsoon Wong; James R Downing Journal: Cancer Cell Date: 2002-03 Impact factor: 31.743
Authors: C H Pui; L S Frankel; A J Carroll; S C Raimondi; J J Shuster; D R Head; W M Crist; V J Land; D J Pullen; C P Steuber Journal: Blood Date: 1991-02-01 Impact factor: 22.113
Authors: Marina I Garín; Chung-Ching Chu; Dela Golshayan; Eva Cernuda-Morollón; Robin Wait; Robert I Lechler Journal: Blood Date: 2006-11-16 Impact factor: 22.113
Authors: M Frank Erasmus; Ksenia Matlawska-Wasowska; Ichiko Kinjyo; Avanika Mahajan; Stuart S Winter; Li Xu; Michael Horowitz; Diane S Lidke; Bridget S Wilson Journal: Sci Signal Date: 2016-11-29 Impact factor: 8.192
Authors: Jacquelyn M Lykken; Mayuka Horikawa; Veronique Minard-Colin; Masahiro Kamata; Tomomitsu Miyagaki; Jonathan C Poe; Thomas F Tedder Journal: Blood Date: 2016-02-17 Impact factor: 22.113
Authors: Kamil Wdowiak; Tomasz Francuz; Enrique Gallego-Colon; Natalia Ruiz-Agamez; Marcin Kubeczko; Iga Grochoła; Jerzy Wojnar Journal: Int J Mol Sci Date: 2018-01-10 Impact factor: 5.923
Authors: Helicia Paz; Eun Ji Joo; Chih-Hsing Chou; Fei Fei; Kevin H Mayo; Hisham Abdel-Azim; Haike Ghazarian; John Groffen; Nora Heisterkamp Journal: J Exp Clin Cancer Res Date: 2018-03-27